Last updated: February 20, 2026
What is the Product?
NDC 72603-0152 is a prescription drug marketed as Blenrep (belantamab mafodotin-blmf), a targeted monoclonal antibody for multiple myeloma treatment. Approved by the FDA in August 2020, it is indicated for adult patients who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Market Size and Competitors
Market Context
The multiple myeloma market is expanding due to increased diagnosis rates and the development of novel therapies. The global multiple myeloma market was valued at approximately USD 15 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 10% through 2027.
Key Competitors
- Darzalex (daratumumab): Annual sales exceeding USD 4 billion (as of 2022).
- Pomalyst (pomalidomide): USD 1.5 billion.
- Kyprolis (carfilzomib): USD 1.1 billion.
- Empliciti (elotuzumab): USD 600 million.
Blenrep’s market share is limited due to its recent approval, but it targets a niche patient segment—relapsed/refractory multiple myeloma (RRMM)—where unmet needs for effective options persist.
Prescription Trends
- Approximately 25,000 new cases globally annually.
- About 3-4 treatments per patient over the course of disease.
- Currently, around 20,000 eligible patients in the U.S. market, with potential for expansion.
Pricing Overview
Current Launch Price
- List price per vial: USD 5,100.
- Typical dosing: 2.5 mg/kg once every three weeks.
- Estimated average treatment course: 6 cycles (~18 weeks).
Price Calculation
- Approximate per-treatment cost: USD 30,600.
- Total average treatment cost for a patient: USD 183,600.
Reimbursement and Market Access
- Reimbursed primarily through commercial insurance and Medicare.
- Prevalence of coverage restrictions due to high costs.
Market Dynamics
Prices are influenced by:
- Competitive landscape.
- Payer negotiations.
- FDA's decision on pricing benchmarks for orphan drugs.
- Potential discounts or patient assistance programs lowering net price.
Price Projections (2023-2027)
| Year |
Expected Price per Vial |
Average Treatment Cost |
Market Penetration |
Notes |
| 2023 |
USD 5,100 |
USD 183,600 |
10% of eligible |
Initial launch market penetration |
| 2024 |
USD 4,950–5,100 |
USD 177,000–183,600 |
15% |
Slight price stabilization, increased adoption |
| 2025 |
USD 4,800–5,000 |
USD 172,000–180,000 |
20% |
Competitive pressures, biosimilar considerations |
| 2026 |
USD 4,700–4,900 |
USD 168,000–175,200 |
25% |
Payer negotiations, market expansion |
| 2027 |
USD 4,600–4,800 |
USD 164,400–171,600 |
30% |
Price reductions, expanded approved uses |
Assumptions:
- Price reductions reflect competitive pressures and payer negotiations.
- Market share increases due to improved clinical outcomes and expanded indications.
- No significant regulatory or reimbursement barriers.
Regulatory and Reimbursement Factors
- FDA approval covers adult patients with relapsed/refractory multiple myeloma.
- CMS and commercial payers are implementing value-based reimbursements.
- The European Medicines Agency (EMA) approved Blenrep in 2021, expanding international market potential.
- Pricing negotiations and payer policies are key factors in net price realization.
Summary Assessment
Blenrep is positioned within a lucrative but highly competitive segment. Its high list price reflects targeted therapy status and the orphan drug designation. Market penetration will heavily depend on efficacy, safety profile, payer acceptance, and competitive launches.
Potential upside exists if the drug demonstrates superior outcomes or if broader indications receive approval. Downward pressure on prices will likely emerge from payer negotiations and biosimilar competition, expected around 2027.
Key Takeaways
- NDC 72603-0152 (Blenrep) entered a $15 billion global market with increasing treatment options.
- Initial list price stands at approximately USD 5,100 per vial, with treatment costs averaging USD 183,600.
- Market projections show gradual price declines and growth in market share through 2027.
- Revenue potential aligns with expanding indications and improved clinical outcomes.
- Market access challenges and competitive pressures will influence pricing and sales volumes.
FAQs
1. What factors influence Blenrep's pricing?
Pricing is driven by regulatory approval, clinical efficacy, payer negotiations, treatment costs, and competitive landscape.
2. How does Blenrep compare to its competitors?
It targets relapsed/refractory multiple myeloma similar to Darzalex but has a different mechanism of action and dosing schedule, affecting positioning and reimbursement potential.
3. What is the outlook for price changes over the next five years?
Prices are expected to decline gradually due to competitive pressures, biosimilar entry, and payer negotiations, with an average reduction of around 10% from the initial list price.
4. What is the growth potential for Blenrep's market?
Expansion in approved indications and increased adoption could raise annual sales, but market share gains depend on efficacy, safety, and reimbursement terms.
5. Are biosimilar competitors likely?
Given the orphan designation and current biotech landscape, biosimilars are less imminent but could enter post-patent expiration, around 2030.
Sources:
[1] IQVIA. (2022). Global Oncology Market Data.
[2] FDA. (2020). Blenrep (belantamab mafodotin-blmf) approval announcement.
[3] Evaluate Pharma. (2022). Oncology Market Analysis.
[4] Centers for Medicare & Medicaid Services (CMS). (2022). Reimbursement frameworks for oncology drugs.
